Skip to main content
TipRanks
Go Ultimate75% OFF

CorVel (CRVL) AI Stock Analysis

185 Followers
CRVL

CorVel

(NASDAQ:CRVL)

Select Model
Rating:83Outperform
Price Target:$100.00â–²(12.52% Upside)
Action:reiterated
Date:11/06/26

The score is driven primarily by excellent financial performance, including strong profitability, capitalization, and cash generation. Positive technical momentum and shareholder governance support the rating, while the elevated P/E ratio and near-overbought momentum indicators reduce upside.

Positive Factors
ProfitabilityCorVel combines improving net margins with solid EBIT and EBITDA margins, indicating disciplined operations and meaningful profitability from its healthcare management services. Sustained operating efficiency can support reinvestment, customer value delivery, and resilience across the next several quarters.
Negative Factors
Moderating Revenue GrowthRevenue is still expanding, but slower growth than in earlier periods could limit operating leverage and make future earnings gains more dependent on margin improvement. Moderation also raises the importance of continued customer adoption and expansion of CorVel’s service offerings.

CorVel Key Performance Indicators (KPIs)

Revenue by Service LineBreaks down sales across CorVel’s business lines (claims administration, bill review, network and specialty services), showing which areas drive growth and profits. A shift toward higher‑margin or rapidly growing services indicates better future earnings power, while concentration in one line increases vulnerability to pricing pressure, regulatory changes, or competitive loss.

$0.00$50.00M$100.00M$150.00M$200.00M$250.00MJun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Network Solutions has become the faster‑growing engine, propelled by CERIS and recent large payer wins, and is poised to drive disproportionate revenue and margin upside as multiyear implementations scale in the back half of the year; prepaid realization also shortens cash conversion. Patient Management remains the larger, steadier business but is delivering only low single‑digit growth, so overall upside depends on Network Solutions execution, automation to normalize elevated staffing, and whether the timing‑related CERIS benefit proves repeatable.

Data provided by:The Fly

CorVel (CRVL) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%CRVL+20.34%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.47B
Dividend Yield
―
Average Volume (3M)
189.27K
Price to Earnings (P/E)
37.3
Beta (1Y)
0.30
Revenue Growth
8.29%
EPS Growth
16.35%
Country
US
Employees
5,239
Sector
Financial
Sector Strength
68
Industry
Insurance - Brokers

CorVel Business Overview & Revenue Model

Company Description

CorVel Corporation delivers comprehensive solutions designed to assist employers, third-party administrators, insurance providers, and government entities in effectively managing healthcare claims. The company focuses on controlling medical expenditu...

How the Company Makes Money

CorVel makes money by charging customers (such as employers, insurance companies, and third-party administrators) fees for delivering healthcare and claims-related management services and for access to its technology-enabled workflows. Key revenue st...

CorVel Earnings Call Summary

Earnings Call Date:May 20, 2026(Q4-2026)|% Change Since:51.09%|Next Earnings Date:Feb 02, 2027
Earnings Call SentimentPositive

The call presented multiple strong operational and financial positives: revenue and EPS growth (quarterly and fiscal), improved margins, robust new bookings (+56%) and pipeline expansion (RFPs +20%), cash generation, a debt-free balance sheet and aggressive share repurchases. Strategic wins for CERIS, expansion of prepaid solutions and continued AI/automation investments position the company for scalable growth. Offset risks include a higher effective tax rate, some one-time/timing-driven CERIS benefits that may not fully recur, only low single-digit growth in patient management, near-term staffing costs, and industry headwinds including rising claims severity and cybersecurity risks. Overall, the favorable results, expanding bookings and strong cash/return-of-capital program materially outweigh the noted challenges.

Positive Updates

Quarterly Revenue Growth
March quarter revenues were $249 million, up 7% year-over-year from $232 million in March 2025.

Negative Updates

Higher Effective Tax Rate
Effective tax rate increased compared to the prior year because the prior year included a discrete benefit from stock option exercises that did not recur, which tempered EPS growth.

Company Guidance

The company guided that momentum from CERIS and recently signed enterprise programs—4 large payer implementations in 2026, including 2 new multiyear partnerships with top‑10 national payers—should drive ongoing revenue and profit tailwinds, with new bookings up 56% year‑over‑year and RFP activity up 20%, and those multiyear bookings expected to contribute meaningfully to revenue and profit growth in the back half of the calendar year as implementations scale; management also said a timing‑related CERIS benefit added $0.02 to EPS in the period. They expect prepaid solutions (revenue realization in about 1–2 months versus ~6+ months for postpaid) and expanded automation/AI to deliver sustained productivity gains, normalize elevated personnel levels as deployments mature, reduce manual work and improve operating leverage through the remainder of the year and into 2027. Supporting this push, CorVel pointed to a strong, debt‑free balance sheet with $233M cash, $66M free cash flow for FY2026, and ongoing share repurchases (872,744 shares repurchased for $56M in FY2026; 366,306 for $20M in Q4; 115.3M total repurchased to date for $868M, ~69% of shares outstanding at an average $7.70), which management said funds continued investment in technology, product expansion and M&A optionality.

CorVel Financial Statement Overview

Summary

Excellent financial strength, supported by improving profitability, very low leverage, strong return on equity, and robust cash generation. The unusually high reported revenue growth and operating-to-free-cash-flow gap are modest cautions.

Income Statement

91Very Positive

Balance Sheet

94Very Positive

Cash Flow

89Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.01B958.53M895.59M795.31M718.56M646.23M
Gross Profit249.26M232.86M209.73M171.69M158.26M152.11M
EBITDA186.23M174.90M150.36M121.35M109.67M108.43M
Net Income121.52M110.34M95.17M76.25M66.36M66.41M
Balance Sheet
Total Assets713.60M642.99M545.98M454.68M393.92M415.25M
Cash, Cash Equivalents and Short-Term Investments269.99M233.07M170.58M105.56M71.33M97.50M
Total Debt33.07M28.11M28.08M31.40M33.76M43.14M
Total Liabilities283.10M248.75M223.99M207.03M191.75M202.85M
Stockholders Equity430.50M394.23M321.99M247.65M202.18M212.40M
Cash Flow
Free Cash Flow127.86M110.28M91.56M70.00M55.97M37.40M
Operating Cash Flow165.13M155.64M127.31M99.24M82.29M67.22M
Investing Cash Flow-37.27M-45.36M-35.76M-29.24M-26.32M-29.82M
Financing Cash Flow-65.32M-47.80M-26.54M-35.76M-82.14M-79.61M

CorVel Technical Analysis

Technical Analysis SentimentPositive
Last Price88.87

Price Trends

50DMA78.86Positive
100DMA71.64Positive
200DMA63.60Positive

Market Momentum

MACD2.42Negative
RSI68.67Neutral
STOCH73.91Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVL, the sentiment is Positive. The current price of 88.87 is above the 20-day moving average (MA) of 84.47, above the 50-day MA of 78.86, and above the 200-day MA of 63.60, indicating a bullish trend. The MACD of 2.42 indicates Negative momentum. The RSI at 68.67 is Neutral, neither overbought nor oversold. The STOCH value of 73.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRVL.

CorVel Risk Analysis

CorVel disclosed 32 risk factors in its most recent earnings report. CorVel reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Increased regulatory scrutiny on use of "big data" techniques, machine learning, and artificial intelligence could impact our business and expose us to increased liability.Q1, 2024

CorVel Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

CRVL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CRVLCRVL83Outperform$4.41B37.3430.20%―8.29%16.35%
AJGAJG81Outperform$72.36B42.707.16%0.97%25.60%3.46%
AONAON74Outperform$71.03B18.1240.38%0.96%3.29%46.05%
WTWWTW73Outperform$30.67B20.2019.92%1.14%4.75%-22.03%
BROBRO71Outperform$24.18B19.929.69%0.93%26.10%8.89%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
CRD.ACRD.A50Neutral$555.84M22.1714.48%2.59%-3.62%-17.84%

* Financial Sector Average

Performance Comparison

-20%0%20%CRVLAONAJGBROCRD.AWTWDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CRVL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CRVLCorvel88.8717.1823.96%
AONAon Plc332.47-10.12-2.95%
AJGArthur J. Gallagher282.2237.8015.46%
BROBrown & Brown72.90-5.92-7.51%
CRD.ACrawford & Company A11.971.2411.57%
WTWWillis Towers Watson Public Limited Company332.5621.767.00%

CorVel Corporate Events

Executive/Board ChangesShareholder Meetings

CorVel Shareholders Back Board, Auditor and Executive Pay

Positive
Aug 11, 2026

At its annual meeting of stockholders held on August 6, 2026, CorVel Corporation shareholders elected six directors to serve until the 2027 annual meeting or until their successors are chosen. The voting results showed broad support for most nominees...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026